Cytokinetics (CYTK) News Today $50.23 -0.89 (-1.74%) As of 01:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Cytokinetics, Incorporated (NASDAQ:CYTK) Shares Sold by Van ECK Associates CorpVan ECK Associates Corp lowered its position in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 24.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 54,364 shares of the biopharmaceutiFebruary 21 at 3:11 AM | marketbeat.comAllspring Global Investments Holdings LLC Has $4.11 Million Stake in Cytokinetics, Incorporated (NASDAQ:CYTK)Allspring Global Investments Holdings LLC decreased its position in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 9.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 84,021 shares of the biopharmaceutical comFebruary 21 at 3:10 AM | marketbeat.comCytokinetics, Incorporated (NASDAQ:CYTK) Given Consensus Recommendation of "Moderate Buy" by AnalystsShares of Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eighteen brokerages that are presently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation, fifteeFebruary 21 at 2:25 AM | marketbeat.comCytokinetics Inc (CYTK) Announces Stock Options and RSUs for New EmployeesFebruary 20 at 6:58 PM | gurufocus.comCytokinetics, Incorporated (CYTK): One of the Most Oversold Healthcare Stocks to Buy NowFebruary 20 at 1:18 PM | insidermonkey.comInsider Sell: Fady Malik Sells 2,000 Shares of Cytokinetics Inc (CYTK)February 20 at 1:52 AM | gurufocus.comFady Ibraham Malik Sells 2,000 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) StockCytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Fady Ibraham Malik sold 2,000 shares of the company's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $45.98, for a total value of $91,960.00. Following the sale, the executive vice president now owns 116,071 shares in the company, valued at $5,336,944.58. The trade was a 1.69 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.February 19 at 5:16 PM | marketbeat.comCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 19 at 4:00 PM | globenewswire.comPeregrine Capital Management LLC Has $7.07 Million Stock Position in Cytokinetics, Incorporated (NASDAQ:CYTK)Peregrine Capital Management LLC raised its position in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 6.7% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 150,343 shares of the biopharmaceutical company's stock after acquiring an additional 9,February 19 at 5:15 AM | marketbeat.comCytokinetics, Incorporated (NASDAQ:CYTK) EVP Sells $91,960.00 in StockFebruary 19 at 4:49 AM | insidertrades.comStifel Nicolaus Reaffirms Their Buy Rating on Cytokinetics (CYTK)February 19 at 1:54 AM | markets.businessinsider.comCytokinetics (CYTK) Expected to Announce Quarterly Earnings on TuesdayCytokinetics (NASDAQ:CYTK) will be releasing earnings after the market closes on Tuesday, February 25, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=548682)February 18 at 5:17 AM | marketbeat.comCytokinetics (NASDAQ:CYTK) Stock Price Up 7.6% - What's Next?Cytokinetics (NASDAQ:CYTK) Stock Price Up 7.6% - Still a Buy?February 15, 2025 | marketbeat.comCytokinetics (NASDAQ:CYTK) Rating Increased to Overweight at Morgan StanleyFebruary 15, 2025 | americanbankingnews.comCytokinetics jumps amid renewed takeover speculationFebruary 14, 2025 | msn.comCytokinetics rumor highlighted in Betaville alertFebruary 14, 2025 | markets.businessinsider.comCytokinetics rumor highlighted in Betaville alertFebruary 14, 2025 | markets.businessinsider.comMorgan Stanley Upgrades Cytokinetics (CYTK)February 13, 2025 | msn.comCytokinetics Inc (CYTK) Announces Upcoming Fourth Quarter Results and Conference CallFebruary 13, 2025 | gurufocus.comCytokinetics to Announce Fourth Quarter Results on February 27, 2025February 13, 2025 | globenewswire.comCytokinetics (NASDAQ:CYTK) Upgraded by Morgan Stanley to Overweight RatingMorgan Stanley raised Cytokinetics from an "equal weight" rating to an "overweight" rating and reduced their price objective for the company from $70.00 to $67.00 in a report on Thursday.February 13, 2025 | marketbeat.comCytokinetics upgraded to Overweight from Equal Weight at Morgan StanleyFebruary 13, 2025 | markets.businessinsider.comMorgan Stanley lifts Cytokinetics stock rating, cuts target to $67February 13, 2025 | msn.comCytokinetics (NASDAQ:CYTK) Reaches New 1-Year Low - Should You Sell?Cytokinetics (NASDAQ:CYTK) Sets New 52-Week Low - Should You Sell?February 13, 2025 | marketbeat.comFMR LLC Reduces Stake in Cytokinetics Inc: A Strategic Portfolio AdjustmentFebruary 12, 2025 | gurufocus.comHarvey Capital Management Inc. Acquires New Position in Cytokinetics, Incorporated (NASDAQ:CYTK)Harvey Capital Management Inc. bought a new position in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 22,105 shares of the biopharmaceutFebruary 12, 2025 | marketbeat.comCytokinetics stock touches 52-week low at $41.69 amid market challengesFebruary 11, 2025 | msn.comCytokinetics appoints Robert Landry to board of directorsFebruary 11, 2025 | markets.businessinsider.comCytokinetics adds pharma veteran Landry to board ahead of drug launchFebruary 11, 2025 | msn.comCytokinetics Appoints Robert E. Landry to BoardFebruary 11, 2025 | tipranks.comCytokinetics Inc (CYTK) Strengthens Board with Appointment of Former Regeneron CFOFebruary 11, 2025 | gurufocus.comCytokinetics Names Robert E. Landry to Board of DirectorsFebruary 11, 2025 | globenewswire.comCitigroup Initiates Coverage of Cytokinetics (CYTK) with Buy RecommendationFebruary 8, 2025 | msn.comWhy Cytokinetics, Incorporated (CYTK) Is Among the Best Healthcare Stocks To Buy According to AnalystsFebruary 8, 2025 | msn.comCiti sets $86 price target on Cytokinetics stock with buy ratingFebruary 8, 2025 | msn.comCytokinetics (NASDAQ:CYTK) Hits New 12-Month Low - Should You Sell?Cytokinetics (NASDAQ:CYTK) Reaches New 52-Week Low - Here's What HappenedFebruary 7, 2025 | marketbeat.comCytokinetics' (CYTK) "Market Outperform" Rating Reiterated at JMP SecuritiesJMP Securities reissued a "market outperform" rating and issued a $78.00 price target on shares of Cytokinetics in a research note on Friday.February 7, 2025 | marketbeat.comCytokinetics (NASDAQ:CYTK) Coverage Initiated at CitigroupCitigroup initiated coverage on Cytokinetics in a report on Friday. They set a "buy" rating and a $86.00 target price on the stock.February 7, 2025 | marketbeat.comJMP Securities maintains Cytokinetics stock with $78 targetFebruary 7, 2025 | msn.comFY2024 Earnings Forecast for Cytokinetics Issued By B. RileyCytokinetics, Incorporated (NASDAQ:CYTK - Free Report) - Research analysts at B. Riley boosted their FY2024 earnings per share estimates for shares of Cytokinetics in a research note issued to investors on Wednesday, February 5th. B. Riley analyst M. Mamtani now anticipates that the biopharmaceutFebruary 7, 2025 | marketbeat.comabrdn plc Acquires 102,457 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)abrdn plc grew its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 29.4% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 450,513 shares of the biopharmaceutical company's stock after purchasing an additional 102,457 shares durFebruary 7, 2025 | marketbeat.comJMP Securities Sticks to Their Buy Rating for Cytokinetics (CYTK)February 7, 2025 | markets.businessinsider.comCamzyos news has negative readthroughs for Cytokinetics, says BofAFebruary 6, 2025 | markets.businessinsider.comCytokinetics share weakness on updated Camzyos REMS overdone, says TruistFebruary 6, 2025 | markets.businessinsider.comCytokinetics' (CYTK) "Buy" Rating Reiterated at Needham & Company LLCNeedham & Company LLC restated a "buy" rating and issued a $72.00 price objective on shares of Cytokinetics in a research report on Thursday.February 6, 2025 | marketbeat.comCytokinetics (NASDAQ:CYTK) Shares Down 8.5% - Here's WhyCytokinetics (NASDAQ:CYTK) Trading Down 8.5% - Here's WhyFebruary 6, 2025 | marketbeat.comCytokinetics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 5, 2025 | globenewswire.comCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 4, 2025 | globenewswire.comCytokinetics' SWOT analysis: aficamten potential drives stock outlookFebruary 4, 2025 | msn.comCytokinetics awards $100K to heart disease advocacy groupsJanuary 30, 2025 | msn.com Get Cytokinetics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter. Email Address CYTK Media Mentions By Week CYTK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CYTK News Sentiment▼0.380.60▲Average Medical News Sentiment CYTK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CYTK Articles This Week▼1810▲CYTK Articles Average Week Get Cytokinetics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Teva Pharmaceutical Industries News Summit Therapeutics News Genmab A/S News Intra-Cellular Therapies News Viatris News Moderna News Dr. Reddy's Laboratories News Vaxcyte News Sarepta Therapeutics News Qiagen News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CYTK) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytokinetics, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytokinetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CYTK Stock Alerts